MIL62, an injection therapy approved exclusively in China for neuromyelitis optica spectrum disorder (NMOSD), was found to keep most NMOSD patients free of relapses for up to two years, while being generally safe and well tolerated. That’s according to data from the Phase 1b portion of a single-center…
MIL62
Recent Posts
- Early trial of experimental CAR T-cell therapy seeks people with NMOSD
- Because patients are the reason for the research, we deserve a seat at the table
- Disability in NMOSD patients may worsen even without relapses
- Aging with NMOSD: How I’m facing the future with hope
- Smoking hinders NMOSD relapse recovery, review study shows